Oncosil Medical Ltd · ASX:OSL
Oncosil Medical — Shareholder Meeting (October 2018)
27 slides from Oncosil Medical's shareholder meeting presentation, Oct 30, 2018
Slide 1: Annual General Meeting - Advancing Pancreatic Cancer Treatment
For personal use only Annual General ASX.OSL Meeting 30 October 2018 Advancing Pancreatic Cancer Treatment OncoSil Medical 1
Slide 2: Investment Highlights
OncoSil Medical | Investment Highlights For personal use only 1 Clear Commercialising a breakthrough implantation radiation mission treatment for Pancreatic cancer 2 Current and previous clinical studies demonstrate: Excellent Local Disease Control Sound Significant reduction in tumour size and
Slide 3: OncoSil is a first in class medical device for pancreatic cancer
OncoSil Medical OncoSilTM is a first in class medical device for the treatment of unresectable locally For personal use only advanced pancreatic cancer First in class technology Share price performance (1 year) Proprietary brachytherapy (internal radiation) medical Price (A$) Volume (k) device 0.3
Slide 4: About the OncoSil device
About the OncoSilTM device An implantable radiotherapy medical device targeting pancreatic cancer For personal use only OncoSilTM is a single-use brachytherapy device Delivered through microparticles: 30-micron silicon particles contain beta-emitting Phosphorus-32 (32P) OncoSilTM Microparticles are
Slide 5: Implantation procedure
Implantation procedure Studies continue to show the device implantation is technically straightforward For personal use only Endoscope guided into the OncoSil™ injected OncoSilTM dose is upper intestine directly into the suspended in a tumour Using CT or real-time imaging, specially formulated the n
Slide 6: Real-Time Visualisation
Real-Time Visualisation Needle Positioning in Pancreatic Mass via Endoscopic Ultrasound (EUS) For personal use only Needle positioning OncoSil™ deposition OncoSil Medical BSI Meeting XXXX 66
Slide 7: SPECT-CT Bremsstrahlung Imaging
SPECT-CT Bremsstrahlung Imaging SPECT-CT Bremsstrahlung Imaging is used to confirm localisation of OncoSil™ For personal use only Imaging types Coronal Sagittal Transverse CT Interaction of beta particles with tissue can SPECT produce bremsstrahlung (note: intensity in gray x-rays which can be scale
Slide 8: OncoSil at a potential value inflection point
OncoSil at a potential value inflection point The Company is well positioned to realise value of OncoSil™ device For personal use only Current focus Before 2015: 2016 to 2018: 2018 onwards: Demonstrate Satisfy regulatory Path to potential obligations commercialisation 4 studies show Secured US F
Slide 9: Clinical pathway overview
Clinical pathway overview PanCO and OncoPaC-1 to inform future studies For personal use only Future focus Phases: Current focus Studies to drive clinical adoption (EU & global) 2 concurrent trials, targeting 65 patients total and secure US FDA approval Trials: PanCO – 45 patients Company exploring c
Slide 10: Efficacy – Local Disease Control Rate
Efficacy – Local Disease Control Rate Radiological response by CT scan assessments For personal use only Local Disease Control Rate (LDCR) at 16 weeks per RECIST 1.1 Intention to Treat Per Protocol (ITT population) (PP population) N= 50 patients enrolled, regardless of N= 42 patients enrolled and im
Slide 11: Efficacy – Volumetric assessments
Efficacy – Volumetric assessments Radiological response by CT scan assessments For personal use only Maximum Percentage Change in Tumour Volume from Baseline at Week 16 Range of Number of Median volumetric Mean volumetric volumetric p-value patients (N*/N) reduction reduction change 40*/42 37% 29.7%
Slide 12: Efficacy – Volumetric assessments (FDG-PET)
Efficacy – Volumetric assessments Radiological response by FDG-PET scan assessments For personal use only Percentage change in TLG from Baseline to Week 12 (%) Percentage change in SUV Max from Baseline to Week 12 (%) Maximum reduction (%) Median reduction (%) Range of change (%) p-value TLG 100 61
Slide 13: Efficacy – Cancer Antigen 19-9 tumour marker
Efficacy – Cancer Antigen 19-9 tumour marker For personal use only % Change in CA 19-9 Tumour Marker from Baseline to Week 16 Median and range of Baseline CA 19-9 134 Number of Participants Number of Participants (37*/42) (49/50) Median CA 19-9 reduction (%) 73 Median 163 Maximum CA 19-9 reduction (
Slide 14: Tumours successfully resected
Tumours successfully resected For personal use only Recap of study context To date, nine implanted study participants have been restaged Study population drawn and have subsequently undergone surgical resection with from patients with curative intent unresectable locally advanced pancreatic cancer
Slide 15: PanCO Study – Interim Analysis Conclusions
PanCO Study – Interim Analysis Conclusions The PanCO study data confirm that the OncoSil™ device, when used in combination For personal use only with contemporary systemic chemotherapy regimens, demonstrates the following: P•• Clinically relevant and statistically significant target tumour (local) d
Slide 16: Significant opportunity for OncoSil
Significant opportunity for OncoSil For personal use only Current available treatment for pancreatic cancer The opportunity for OncoSil Surgery (resection), if diagnosed early enough Only two drugs to have made Chemotherapy (Gemcitabine & Abraxane, FOLFIRINOX) significant improvements in pancr
Slide 17: Positive reception at key conferences
Positive reception at key conferences Early study data presented at 5 leading conferences worldwide For personal use only World Congress of the World Federation Digestive Disease Week ESMO World Congress on of Nuclear Medicine and Biology Washington, June 2018 Gastrointestinal Cancer Melbourne, Apri
Slide 18: Partnering with leading cancer centres
Partnering with leading cancer centres 15 leading cancer centres participating in Global Pancreatic Cancer clinical programme For personal use only Region Centre MD Anderson, Texas Johns Hopkins, Maryland Moffit Cancer Centre Florida Cedars Sinai Hospital, LA Guy’s & St Thomas’, London University of
Slide 19: Clear pathway to commercialisation
Clear pathway to commercialisation Strategic partners provide multiple paths to market to optimise value For personal use only Well positioned for commercialisation Potential paths to market Broad technology platform Treatment for multiple solid tumours Strategic licensing partners in all key geogra
Slide 20: Global opportunity and target markets
UK(Launch market) 1,2 Pancreatic cancer 8,747 Liver cancer 4,186 European Union1,2 For personal use only Pancreatic cancer 79,331 Liver cancer 51,785 Target markets Annual incidence China1,2 Global opportunity United States 1,2 Pancreatic cancer 65,727 Liver cancer 351,000 Pancreatic cancer US>$2.0b
Slide 21: Global Commercial opportunity in excess of $2bn
Global Commercial opportunity in excess of $2bn 130,000 cases p.a in US+EU alone: more than 70,000 of these could benefit from OncoSil For personal use only More than 70,000 relevant Locally OncoSil™ provides a suitable treatment to patients in EU and US alone advanced control the growth of the prim
Slide 22: Sector M&A trends
Sector M&A trends Over A$2bn of acquisitions in February 2018 highlights attraction of early-stage For personal use only Australian biotech to global pharmaceutical players Acquiree Acquirer Consideration A$1.9 billion1 A$502 million1 A$120 million1 Date 22 May 2018 22 Feb 2018 6 Feb 2018 Premium 78
Slide 23: Board of Directors
Board of Directors For personal use only • Board and management are experienced leaders in the pharmaceutical and medical device space, having held senior positions at Cochlear (ASX:COH), Sirtex Medical (ASX:SRX), ABIVAX, Baxter International, Roche and more • Extensive leadership experience guiding
Slide 24: Highly experienced management team
Highly experienced management team Revamped leadership team For personal use only • Management team experienced leaders in the medical device space having held senior positions at Sirtex Medical (ASX:SRX) • Extensive leadership experience in clinical studies, commercialisation and manufacturing & op
Slide 25: Key catalysts in CY 2018
Key catalysts in CY 2018 Revamped leadership team For personal use only Target CE Mark Certification CE Mark Target EU first sales Completion of PanCO clinical study, with 50 patients enrolled, 42 patients implanted Global Pancreatic OncoPaC-1 trial progress: 8 patients currently enrolled &
Slide 26: Important notice
Important notice For personal use only This Presentation has been prepared by OncoSil Medical Ltd (ASX:OSL) (OncoSil or the Company) to provide an overview of the Company. This Presentation and the information contained may require further explanation and/or clarification. Accordingly, this Presenta
Slide 27: Daniel Kenny, CEO & Managing Director
For personal use only Daniel Kenny CEO & Managing Director E: daniel.kenny@oncosil.com.au OncoSil Medical Ltd www.oncosil.com.au T: +61 2 9223 3344 F: +61 2 9252 3988 OncoSil Medical 27